GHK-Cu Side Effects: Measured, Reported, and Unknown

GHK-Cu Side Effects: The Short Answer

The most common side effect of GHK-Cu Explore PeRxGHK-CuThe Skin Rejuvenation PeptideView peptide injections is the site itself: a pink patch, a small bruise, sometimes a brief sting. The PeRx label covers it in one line, "Mild redness or bruising at the injection site is normal," and that line is the closest thing to a counted side effect this peptide has. Headaches, fatigue, nausea and the "copper uglies" come from forums, not from a study that tallied them.

The human trials are topical: a facial cream for twelve weeks, an eye cream, a thigh-skin collagen study. No published trial has injected GHK-Cu into people, so no measured rate exists for anything that follows an injection.

What Has Been Measured (Topical Trials) and What Has Not (Injection)

The human evidence is cosmetic: a facial cream used for 12 weeks by 71 women with photoaged skin, an eye cream tested on 41 women, and a thigh-skin study in which GHK-Cu raised collagen in more volunteers than vitamin C or retinoic acid cream, known mostly through two reviews by Loren Pickart, who discovered the peptide. The reviews state that no safety issues arose in any cosmetic or wound-healing study and that the peptide has been used in cosmetics for decades "without any adverse effects." Pickart founded a company that sells copper peptide products, so the summary is not independent, and those trials scored wrinkles, not adverse events; silence in a cosmetic study is weaker evidence than a counted zero.

Pickart L, Vasquez-Soltero JM, Margolina A. "GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration." BioMed Research International. 2015;2015:648108. PMID 26236730. View study

Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data." International Journal of Molecular Sciences. 2018;19(7):1987. PMID 29986520. View study

The one independent randomized study of topical GHK-Cu is small. In 2006 facial plastic surgeons randomized patients to GHK-Cu skin care, or none, after carbon dioxide laser resurfacing; thirteen finished. Blinded evaluators found no difference in how fast the post-laser redness cleared and none in wrinkles, though patients using the copper peptide rated their own skin higher. For this page the redness is the point: GHK-Cu on freshly lasered skin neither prolonged nor shortened it.

Miller TR, Wagner JD, Baack BR, Eisbach KJ. "Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin." Archives of Facial Plastic Surgery. 2006;8(4):252-259. PMID 16847171. View study

Injection is a different evidence base. Pickart’s group injected GHK into rats, mice and pigs and reported faster healing of wounds elsewhere on the body; from that work the 2015 review guesses that 100 to 200 mg might be needed in a person, and says even that may be an overestimate. No pharmacokinetic, toxicology or safety study of injected GHK-Cu in humans has been published. The 2 mg PeRx prescribes is a prescribing convention, which the GHK-Cu dosage chart Read nextGHK-Cu Dosage Chart: Units, Schedule, Copper MathSearch for a GHK-Cu dosage chart and you get a Reddit thread and a handful of research-vendor pages, all quoting 1 to 2 mg per injection as if a trial had set it. No trial did. The human GHK-Cu data is almost entirely topical, and the injection figures are clinic convention. This page lays out those conventions as the ranges they are, then the one dose a licensed provider actually prescribes through PeRx: 20 units, 2 mg, Monday through Friday, from a 10 mg/mL vial. Units, weekly totals, the copper arithmetic, timing and missed doses, as of October 1, 2026.Read article explains.

U.S. Food and Drug Administration. "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." Category 1 entry for GHK-Cu (except for injectable routes of administration). Updated May 14, 2026. View study

Injection-Site Reactions: What Is Normal and What Is Not

GHK-Cu goes under the skin once a day, five days a week. A faint pink patch, a small bruise, and a sting that fades within a minute or two are the expected range. The blue to violet tint of the solution is the copper complex. Some patients find the sting sharper than with other peptides; that is unmeasured. What changes after the sting, week by week, is on GHK-Cu before and after Read nextGHK-Cu Before and After: Results, Week by WeekMost GHK-Cu before-and-after pages show a serum result and describe an injection, or describe an injection and cite nothing. The human results that exist come from 12-week trials of creams on the faces of a few dozen women. No published trial has measured what injected GHK-Cu does to anyone. This guide keeps those facts apart from what patients on the injectable protocol report, lays out the week-by-week picture with its sources attached, and shows you how to photograph and track your own skin so the comparison means something.Read article . Rotate sites by a finger-width each day; where to inject GHK-Cu Read nextWhere to Inject GHK-Cu: Sites and RotationGHK-Cu goes under the skin, once a day, five days a week. That schedule puts more demand on your rotation habit than a twice-weekly peptide does, and copper brings two handling rules nothing else in the catalog has. Here is how patients actually run it at home.Read article maps the rotation.

Copper allergy is the question underneath the rash line. Copper has a low sensitization potential in predictive tests, and a 2004 review found unambiguous cases of copper sensitization extremely rare, mostly from intrauterine devices or dental metal. A vial reaction can also come from the peptide or an excipient, so hives or a rash after a dose is a reason to stop and contact the care team.

Hostynek JJ, Maibach HI. "Copper hypersensitivity: dermatologic aspects." Dermatologic Therapy. 2004;17(4):328-333. PMID 15327478. View study

The Copper Question, With the Arithmetic

GHK-Cu is one copper ion held by a three-amino-acid peptide. The peptide weighs about 340 g/mol, the copper ion 63.5, and the complex is listed at roughly 403 g/mol, so copper is 63.5 divided by 403, about 16 percent by weight. A 2 mg dose, the 20 units PeRx prescribes from a 10 mg/mL vial, carries 2 times 0.158, about 0.32 mg of copper. Five doses a week is about 1.6 mg, roughly 0.23 mg a day averaged over the week; the whole 5 mL vial holds about 8 mg across five weeks.

The comparison that matters is dietary. The adult Recommended Dietary Allowance for copper is 0.9 mg a day and the Tolerable Upper Intake Level is 10 mg a day, so an injection day adds about a third of a day’s recommended copper and about 3 percent of the upper limit. The limit was set for copper eaten, of which the gut absorbs only part, while an injection delivers all 0.32 mg; even so, a week of GHK-Cu carries less copper than two days of the recommended diet.

National Institutes of Health, Office of Dietary Supplements. "Copper: Fact Sheet for Health Professionals." Recommended Dietary Allowances and Tolerable Upper Intake Levels for copper. View study

The copper arrives bound: Pickart’s 2015 review summarizes chemistry showing that copper’s redox activity is quieted while the ion is held by the tripeptide, which lets it carry copper into cells without the damage free copper causes. That is test-tube chemistry. And nobody has measured it in a patient: no study has tracked serum copper or ceruloplasmin in people injecting GHK-Cu, so the arithmetic is a calculation, not a lab result.

Screening is for the people the arithmetic does not protect. In Wilson disease the body cannot excrete copper normally and it accumulates in the liver and brain; it is inherited and can first appear at any age. For that disorder and other copper-handling disorders the problem is the direction of the dose, not its size, so GHK-Cu is screened out, as it is for anyone on a copper chelator or zinc therapy for such a condition. A past abnormal copper or ceruloplasmin result belongs on the intake form.

Bandmann O, Weiss KH, Kaler SG. "Wilson’s disease and other neurological copper disorders." The Lancet Neurology. 2015;14(1):103-113. PMID 25496901. View study

Vitamin C, Copper Supplements, and Other Things to Keep Apart

The PeRx prescription carries two rules no other single peptide in the catalog has: "Do not take copper supplements while using this peptide," and "Do not apply Vitamin C serums or take Vitamin C supplements within 2 hours of your injection." Neither comes from a clinical trial, because none exists.

The copper rule is not about toxicity at these amounts. It exists because copper status has never been measured in injected patients, and a single added copper source keeps that unknown interpretable. A standalone copper supplement adds a second variable; a multivitamin that lists copper belongs on your intake form.

The vitamin C rule is chemistry. Ascorbic acid is a reducing agent, and with copper or iron present it reduces the metal to a form that drives free-radical reactions; a 1996 review titled the pairing "catalytic metals, ascorbate and free radicals: combinations to avoid." The two-hour gap applies that to an injection: a vitamin C serum on the site, or a high-dose supplement circulating as the complex is absorbed, is what the rule avoids. That is test-tube chemistry, not a trial in people, and the instruction names serums and supplements; the vitamin C in a meal is not the target.

Buettner GR, Jurkiewicz BA. "Catalytic metals, ascorbate and free radicals: combinations to avoid." Radiation Research. 1996;145(5):532-541. PMID 8619018. View study

GHK-Cu and Cancer: What Was Studied and What Was Not

The cancer question gets confident answers online in both directions. The first study is uncomfortable for the marketing. The paper that announced the peptide, in Nature New Biology in 1973, is titled "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver." In culture, the serum factor that kept normal liver cells alive also made liver tumor cells grow. That is a dish of cells, not a cancer in a person.

Pickart L, Thaler MM. "Tripeptide in human serum which prolongs survival of normal liver cells and stimulates growth in neoplastic liver." Nature New Biology. 1973;243(124):85-87. PMID 4349963. View study

The findings cited for the opposite view are computational. In 2010 a Singapore group defined a 54-gene signature marking early-stage colorectal cancers prone to metastasis, then searched the Broad Institute’s Connectivity Map for compounds that reversed them. Two came up, GHK and the plant alkaloid securinine, and GHK reversed about 70 percent of the signature. Pickart’s group later reported from the same database that GHK raises expression of caspase and DNA-repair genes, and their 2018 review describes a 1983 mouse experiment in which GHK-Cu plus vitamin C suppressed a transplanted sarcoma, unpublished until 2014.

Hong Y, Downey T, Eu KW, Koh PK, Cheah PY. "A 'metastasis-prone' signature for early-stage mismatch-repair proficient sporadic colorectal cancer patients and its implications for possible therapeutics." Clinical & Experimental Metastasis. 2010;27(2):83-90. PMID 20143136. View study

Pickart L, Vasquez-Soltero JM, Margolina A. "GHK and DNA: resetting the human genome to health." BioMed Research International. 2014;2014:151479. PMID 25302294. View study

Campbell JD, McDonough JE, Zeskind JE, et al. "A gene expression signature of emphysema-related lung destruction and its reversal by the tripeptide GHK." Genome Medicine. 2012;4(8):67. PMID 22937864. View study

So the ledger reads: one 1973 cell-culture finding in which the peptide stimulated tumor cells, several computational signals and one mouse experiment pointing toward suppression, and zero human studies of cancer incidence, recurrence or progression in people given GHK-Cu by any route. No animal carcinogenicity study exists either. Calling GHK-Cu anti-cancer reads a database as a trial; saying it feeds tumors reads a 1973 dish the same way. Nothing is established either way, which is why active or recent cancer is a screening flag and a conversation for your oncologist first.

Skin Reactions, Flushing, and the "Copper Uglies" Claim

Search any skincare forum and you will find the "copper uglies," a stretch of weeks in which skin on a copper peptide serum looks worse before it improves. It is anecdote, uncounted, and the usual explanation, that GHK-Cu steps up the enzymes that clear old collagen before new collagen catches up, is a mechanism borrowed from cell studies, not a demonstrated cause. Nothing equivalent has been described for injected GHK-Cu. Nobody has looked, and a cream at cosmetic concentrations is a different exposure from 2 mg into circulation. More in the GHK-Cu guide Read nextGHK-Cu Peptide: Benefits, Injections & EvidenceIn 1973, a biochemist at UCSF discovered that young blood makes old cells act young. The molecule responsible was the GHK peptide, a tiny copper-binding tripeptide that drops 60% by age 60 and influences thousands of your genes. Today, TikTok sells it as a $20 face cream. The injectable version does something fundamentally different: it reaches every tissue in your body and signals all of them to start repairing. Here's why that distinction matters more than any skincare trend.Read article and in GHK-Cu after GLP-1 weight loss Read nextGHK-Cu for Skin After GLP-1 Weight LossThe honest version. Ozempic face is not something the drug did to your skin, it is what a face looks like when it loses fat quickly. That distinction decides which fixes are even in the right category. GHK-Cu has real evidence behind it for collagen and skin quality, and it has hard limits that nobody selling it likes to mention.Read article .

Flushing, headache, a tired afternoon and mild nausea appear on peptide forums for nearly every injectable, and GHK-Cu is no exception. None has a number attached or a mechanism that points to this peptide. Our peptide side effects guide Read nextPeptide Side Effects: Normal vs. Red Flag (2026)Most peptide side effects are mild local reactions that resolve in a day. A smaller set of systemic effects depends on the pathway the peptide acts on. And a third category, the one worth paying attention to, points to a problem with the product or the patient that should pause the protocol. Here is how to tell them apart.Read article covers what is common to the route. If one tracks the injection day after day past the first couple of weeks, report the pattern.

Long-Term Use: The Honest Unknown

Standalone GHK-Cu at PeRx is written for continuous use with no scheduled break. Nobody knows what a year of injected GHK-Cu does, because nobody has studied it: no human pharmacokinetics, no repeat-dose toxicology, no carcinogenicity study, no injected cohort followed over time. Indirectly, the body makes this peptide, plasma levels fall from around 200 ng/mL in young adults to about 80 ng/mL by age 60, and decades of cosmetic use have produced no safety signal. Those are reasons the risk may be low, not measurements of it.

Two long-run questions are specific to this molecule. Copper: at about 1.6 mg a week in a person who handles copper normally, accumulation is not expected, because the body regulates copper through absorption and biliary excretion, but that is dietary physiology, not a blood test in an injected patient. Remodeling: a signal that tells fibroblasts to build and rework tissue, applied continuously, has no documented downside and no documented upside beyond 12-week skin studies. Decide in advance when you will take stock, as peptide long-term safety Read nextAre Peptides Safe Long-Term? What the Data SaysMost safety questions about peptides assume the timeframe is one or two cycles. The harder question is what happens after a year, three years, or a decade. The honest answer is that peptides fall into three buckets: ones with multi-decade clinical data, ones with several years of safety record but limited long-term studies, and ones where the long-term picture is genuinely incomplete. Here is the bucket each peptide is in and what monitoring matters.Read article and peptide safety monitoring Read nextPeptide Safety Monitoring: Signals During TherapyThe most important safety tool on peptide therapy is your own attention. Most peptides are well tolerated, and the side effects people do notice are usually mild and easy to read once you know what is normal, what is worth mentioning, and what means stop and call your provider. This guide is about understanding your body on a peptide: the common symptoms, where your limits are, and when to reach out.Read article lay out.

Who Gets Screened Out, and Why

A licensed provider reviews every intake before GHK-Cu is compounded. What providers review before prescribing Read nextWhat Providers Review Before Prescribing PeptidesWhen your intake reaches a licensed provider, it is not a rubber stamp. There is a specific list they run down before any peptide is approved: the conditions that change whether a peptide is safe, the medication classes that have to be cross-checked, and the reasons an order gets sent back or declined. Here is that list, from the provider’s side of the screen.Read article covers the general process.

Routine lab work is not required to start GHK-Cu; lab work before starting peptides Read nextLab Work Before Starting PeptidesThe honest answer to "what bloodwork do I need before peptides?" is: it depends on the peptide, and for many of them the answer is none. Some sites will tell you to buy a full baseline panel before anything, because they sell the panel. Here is the real picture, which peptides typically need no labs, where a provider may want to check IGF-1 and a metabolic panel, and why the decision belongs to the provider reviewing your history rather than to a checklist.Read article explains why cosmetic and healing peptides generally need none. A past abnormal copper or ceruloplasmin result, or a family history of Wilson disease, belongs on the intake form.

GHK-Cu

Some side-effect risk with any injectable lives in the vial: a guessed concentration or an unverified source. PeRx GHK-Cu is prescribed by a licensed provider after screening and compounded at a US-based, state-licensed 503A pharmacy at a fixed 10 mg/mL. It ships fully reconstituted and ready to use.

$229 for a 5 mL vial, 25 doses, syringes and alcohol swabs included.

Fixed concentration, screened prescription, nothing to mix.

View GHK-Cu

When to Stop and Contact a Clinician

Most of what this page describes needs only a note. A short list needs action, and it is the list on the PeRx prescription.

GHK-Cu Side Effects: Common Questions